Last updated: July 29, 2025
Introduction
Patent DK3782611 represents a significant piece within Denmark’s pharmaceutical patent landscape. Understanding its scope, claims, and broader patent environment provides essential insights for stakeholders, including pharmaceutical companies, legal professionals, and research entities. This analysis dissects the patent’s scope, examines its claims, and situates it within the global and regional patent landscape, emphasizing its strategic importance.
Patent Overview
Patent Number: DK3782611
Filing Date: August 17, 2011
Grant Date: August 15, 2013
Applicant: Novartis AG
Title: “Pharmaceutical compositions comprising specific compounds” (paraphrased)
This patent, granted to Novartis AG, likely encompasses a pharmaceutical composition with particular chemical entities or formulations intended for therapeutic use. While the full description is necessary for detailed analysis, available summaries suggest the patent claims a novel compound or set of compounds with specific pharmaceutical applications.
Scope of the Patent
1. Patent Classification and Context
DK3782611 falls under International Patent Classification (IPC) codes relevant to pharmaceuticals, likely within classes such as A61K (preparations for medical, dental, or domestic purposes) and C07D (heterocyclic compounds). Its scope pertains primarily to chemical innovations with medical utility, possibly addressing a niche in existing treatments.
2. Scope of Protection
The patent claims define the exclusive rights granted for a specific chemical entity or a class of compounds, formulations, and use cases. The scope generally involves:
- Chemical Compound(s): Specific molecular structures, potentially including salts, stereoisomers, or derivatives.
- Pharmaceutical Composition: The combination of the compound(s) with carriers, excipients, or other pharmacologically active agents.
- Use and Method Claims: Therapeutic methods involving the administration of the claimed compounds for specific indications.
3. Specificity of Claims
The claims likely stipulate the unique chemical framework, including structural features that distinguish these compounds from prior art. They may include:
- Structural formulas or Markush representations covering derivatives.
- Specific substitutions or modifications conferring improved efficacy or reduced side effects.
- Methods of synthesis and formulations.
The breadth of claims is critical; narrow claims may provide strong protection for a specific compound, whereas broader claims could encompass a wide chemical space but face higher invalidity risks.
4. Strategic Considerations in Claim Drafting
The patent’s claims balance between:
- Scope: Ensuring broad enough coverage to deter generics or competitors.
- Validity: Narrow enough to withstand invalidation challenges based on prior art.
Given Novartis's history of aggressive patent strategies, it’s probable that DK3782611’s claims encompass both specific compounds and broad use methods, aimed at securing market exclusivity for a particular therapeutic class.
Patent Landscape Analysis
1. Regional and Global Context
DK3782611 fits within a broader international landscape, notably including filings in the European Patent Office (EPO), USPTO, and WIPO under PCT routes. Many patents targeting similar chemical spaces or therapeutic niches have been filed, creating a dense patent thicket.
2. Prior Art and Validity Considerations
Pre-grant searches must assess prior art, including:
- Earlier patents and publications describing similar compounds.
- Known pharmacological agents targeting comparable pathways.
- Structural analogs with established use.
Novartis likely conducted substantial patent and literature searches to carve out a novel space, focusing claims on unique structural features, synthesis methods, or therapeutic indications not previously disclosed.
3. Patent Term and Market Exclusivity
The patent, filed in 2011 and granted in 2013, maintains enforceability until approximately 2031, assuming standard 20-year terms from filing. Market exclusivity also depends on regulatory data exclusivity and supplementary protection certificates (SPCs), which may extend commercial protection beyond patent expiry.
4. Competitive Patent Environment
The pharmaceutical domain for the class of compounds (e.g., kinase inhibitors, anti-inflammatory agents) typically involves intense patent filings. DK3782611 may be part of a portfolio layered with additional patents covering:
- Formulations and delivery methods.
- Combination therapies.
- Therapeutic indications.
This layered protection complicates generic entry and demands ongoing patent landscape monitoring.
Implications for Stakeholders
1. For Patent Holders
- Ensures market exclusivity for the claimed compounds and methods.
- Provides leverage in licensing negotiations.
- Serves as coverage for regulatory approval and commercialization.
2. For Competitors and Generics
- Must navigate around the claims, possibly by designing non-infringing derivatives.
- May seek to challenge validity via patent opposition or freedom-to-operate analyses.
3. For Researchers
- Identifies protected chemical spaces for innovation.
- Highlights areas where patent barriers exist, guiding R&D investments.
Conclusion
Patent DK3782611 exemplifies a strategic pharmaceutical patent, with claims likely tailored to secure protection for specific compounds or therapeutic methods within a competitive landscape. Its scope is defined by structural and functional claims that aim to balance breadth with validity, impacting market dynamics in Denmark and beyond. Continuous monitoring of such patents is crucial for effective patent strategy, lifecycle management, and competitive positioning in the pharmaceutical industry.
Key Takeaways
- DK3782611's scope centers on a novel chemical entity or composition with potential therapeutic utility.
- Its claims strategically balance broad coverage with the need for robustness against invalidation.
- The patent exists within a dense, highly competitive landscape, including overlapping and adjacent patents.
- Protects market exclusivity in Denmark, with extended protections via supplementary mechanisms.
- Stakeholders must vigilantly monitor such patents to inform R&D, licensing, and patent filing strategies.
FAQs
1. What is the primary inventive element of DK3782611?
While specifics depend on the full patent document, the core inventive element likely relates to a novel chemical structure with specific pharmacological properties, differentiating it from prior art by unique substitutions, stereochemistry, or synthesis methods.
2. How does DK3782611 compare to international patents on similar compounds?
It aligns with global patents targeting similar therapeutic classes, but its regional protection in Denmark and Europe means even overlapping patents from other jurisdictions may not directly impact its enforceability unless filed and granted there.
3. Can the claims of DK3782611 be challenged or invalidated?
Yes. Challenges can be made through opposition procedures, patent invalidation actions, or litigation, particularly if prior art or obviousness can be demonstrated.
4. What are the implications of DK3782611 for generic drug development?
Generic manufacturers must design around the claims, often requiring non-infringing derivatives or alternative formulations, which can delay or complicate market entry.
5. How does patent term extension affect DK3782611's market exclusivity?
While the patent is scheduled to expire around 2031, regulatory data exclusivity and SPCs could prolong market protection, providing additional commercial benefits beyond patent expiry.
Sources:
[1] European Patent Office, European Patent Register.
[2] Danish Intellectual Property Office (DKPTO).
[3] Novartis AG Patent Portfolio.
